SAB Biotherapeutics, Inc. 8-K

What Happened
SAB Biotherapeutics, Inc. filed an 8-K reporting that on January 5, 2026 the Board appointed David Zaccardelli, Pharm.D., and Rita Jain, M.D., as Class II directors, effective January 5, 2026. Dr. Zaccardelli was named Chairperson of the Board. Both directors will serve until the company’s 2026 annual meeting of stockholders or until their successors are elected. Samuel J. Reich remains the company’s Chief Executive Officer and continues to serve on the Board.

Key Details

• Appointments were made following the Nominating and Corporate Governance Committee recommendation and at the recommendation of RA Capital Healthcare Fund, L.P., under a July 21, 2025 letter agreement tied to RA Capital’s private placement.
• Each director will receive the same compensation as other non-employee board members per the company’s 2024 Form 10-K disclosures (as may be amended) and has executed customary indemnity agreements.
• Biographies: Dr. Zaccardelli most recently served as President & CEO of Verona Pharma until its acquisition by Merck in Oct 2025 and held senior roles at Dova Pharmaceuticals and United Therapeutics; Dr. Jain currently sits on several public company boards and has served as CMO/EVP at multiple biotech companies.
• The company disclosed a press release announcing these appointments (filed as Exhibit 99.1). The filing states there are no transactions involving either appointee requiring Item 404 disclosure and no family relationships with current officers or directors.

Why It Matters
Board composition and leadership changes can affect strategic oversight and investor confidence. These appointments, which were made pursuant to RA Capital’s board nomination rights, add industry veterans with executive drug-development and commercialization experience and install a new Board Chair. For investors, the key takeaways are the endorsement by a significant investor (RA Capital), continuity of the CEO on the Board, and the company’s formal disclosure of compensation and indemnity arrangements for the new directors.